Aviance Capital Partners, LLC Abbott Laboratories Transaction History

Aviance Capital Partners, LLC

$733 Million
Q3 2024

A detailed history of Aviance Capital Partners, LLC transactions in Abbott Laboratories stock. As of the latest transaction made, Aviance Capital Partners, LLC holds 22,901 shares of ABT stock, worth $2.7 Million. This represents 0.36% of its overall portfolio holdings.

Number of Shares

22,901

Previous 22,962 0.27%

Holding current value

$2.7 Million

Previous $2.39 Million 9.43%

% of portfolio

0.36%

Previous 0.35%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	SELL	$100.07 - $118.13 $6,104 - $7,205	-61 Reduced 0.27%	22,901 $2.61 Million
Q2 2024 Aug 09, 2024	BUY	$100.73 - $112.44 $18,433 - $20,576	183 Added 0.8%	22,962 $2.39 Million
Q1 2024 Apr 17, 2024	BUY	$109.52 - $120.96 $1.42 Million - $1.57 Million	13,009 Added 133.15%	22,779 $2.59 Million
Q4 2023 Feb 06, 2024	BUY	$90.19 - $110.4 $13,618 - $16,670	151 Added 1.57%	9,770 $1.08 Million
Q3 2023 Nov 06, 2023	SELL	$95.53 - $114.62 $36,970 - $44,357	-387 Reduced 3.87%	9,619 $931,000
Q1 2023 May 10, 2023	SELL	$96.86 - $114.01 $10,170 - $11,971	-105 Reduced 1.04%	10,006 $1.01 Million
Q4 2022 Feb 06, 2023	BUY	$95.06 - $111.52 $35,077 - $41,150	369 Added 3.79%	10,111 $1.11 Million
Q3 2022 Nov 09, 2022	BUY	$96.76 - $112.03 $1,741 - $2,016	18 Added 0.19%	9,742 $943,000
Q2 2022 Aug 08, 2022	BUY	$102.07 - $123.37 $5,103 - $6,168	50 Added 0.52%	9,724 $1.06 Million
Q1 2022 May 06, 2022	BUY	$114.02 - $139.04 $17,331 - $21,134	152 Added 1.6%	9,674 $1.15 Million
Q4 2021 Feb 07, 2022	SELL	$115.53 - $141.46 $7,740 - $9,477	-67 Reduced 0.7%	9,522 $1.34 Million
Q3 2021 Nov 12, 2021	SELL	$116.66 - $129.06 $16,215 - $17,939	-139 Reduced 1.43%	9,589 $1.13 Million
Q2 2021 Aug 06, 2021	SELL	$105.79 - $124.53 $15,233 - $17,932	-144 Reduced 1.46%	9,728 $1.13 Million
Q1 2021 Apr 29, 2021	BUY	$108.84 - $128.23 $19,482 - $22,953	179 Added 1.85%	9,872 $1.18 Million
Q4 2020 Feb 12, 2021	BUY	$105.0 - $114.42 $105,000 - $114,420	1,000 Added 11.5%	9,693 $1.06 Million
Q2 2020 Jul 24, 2020	BUY	$76.57 - $98.0 $19,448 - $24,892	254 Added 3.01%	8,693 $795,000
Q1 2020 May 05, 2020	SELL	$62.82 - $91.86 $2,261 - $3,306	-36 Reduced 0.42%	8,439 $666,000
Q4 2019 Feb 07, 2020	BUY	$78.51 - $87.4 $10,206 - $11,362	130 Added 1.56%	8,475 $736,000
Q3 2019 Nov 07, 2019	SELL	$81.84 - $88.74 $116,294 - $126,099	-1,421 Reduced 14.55%	8,345 $698,000
Q2 2019 Aug 12, 2019	SELL	$72.88 - $85.0 $6,340 - $7,395	-87 Reduced 0.88%	9,766 $821,000
Q1 2019 May 01, 2019	SELL	$66.22 - $80.06 $1,986 - $2,401	-30 Reduced 0.3%	9,853 $788,000
Q4 2018 Feb 11, 2019	BUY	$65.56 - $74.27 $4,064 - $4,604	62 Added 0.63%	9,883 $714,000
Q3 2018 Nov 09, 2018	BUY	$60.81 - $73.36 $5,168 - $6,235	85 Added 0.87%	9,821 $720,000
Q2 2018 Aug 10, 2018	SELL	$57.57 - $63.54 $1.27 Million - $1.4 Million	-22,000 Reduced 69.32%	9,736 $593,000
Q1 2018 May 03, 2018	BUY	$56.27 - $63.62 $25,715 - $29,074	457 Added 1.46%	31,736 $1.9 Million
Q3 2017 Nov 09, 2017	BUY	$48.06 - $53.64 $1.5 Million - $1.68 Million	31,279	31,279 $1.67 Million

Others Institutions Holding ABT

# of Institutions

3,186

Shares Held

1.3B

Call Options Held

8.74M

Put Options Held

8.08M

View Full List

About ABBOTT LABORATORIES

Ticker ABT
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 1,751,219,968
Market Cap $206B
Description
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for t...

More about ABT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Aviance Capital Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Aviance Capital Partners, LLC with notifications on news.

Account

Aviance Capital Partners, LLC Abbott Laboratories Transaction History